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THE EFFECT OF CELECOXIB ON PAIN AND PHYSICAL 
FUNCTION IN KNEE OSTEOARTHRITIS PATIENTS 
TP Stitik, DM Stiskal, JH Kim, L Schoenherr, N Shenoy, M Coba 
Physical Medicine and Rehabilitation, UMDNJ- New Jersey 
Medical School, Newark, NJ 
Introduction: A Cox-II inhibitor such as celecoxib (Celebrex) is 
one of the recommended pharmacologic treatments for medical 
management of knee osteoarthritis (OA). Few studies exist that 
examine the relationship between Cox-II inhibitor use and out- 
come measures such as quadriceps strength, pain and function 
in patients with knee OA. The aim of this pilot study was to assess 
the effectiveness of celecoxib in improving quadriceps strength, 
function and knee pain. 
Methods: Using a multiple baseline, within-subjects repeated 
measures design; we recruited six subjects who met inclusion 
criteria that are consistent with the American College of Rheuma- 
tology Guidelines for the diagnosis of knee OA. All subjects were 
evaluated for 3 baseline visits at 2 week intervals to capture 
an accurate measure of their pre-medication status. At the third 
baseline visit, subjects were then given a six week course of 
celecoxib (200 mg/d).Outcome measures continued to be col- 
lected at 2 week intervals during the 6 week course of medi- 
cation. Dependant variables included WOMAC (Western Ontario 
and McMaster Universities Osteoarthritis Index) pain, stiffness 
and function scales; left and right quadriceps isometric strength; 
and the "Timed Get Up and Go Test" (TUG). A repeated mea- 
sures ANOVA was employed to determine differences from base- 
line measures. 
Results: The mean of the three baseline measures were aver- 
aged and this value was then used to compare with scores ob- 
tained at 2, 4, and 6 weeks during the course of medication. Sig- 
nificant reductions in pain (F = 17.83, p <.000), stiffness (F = 
33.76, p <.000) and function (F = 22.28, p <.000) were found. 
Post-hoc analyses revealed each of the four measures differed 
significantly from the other three for pain (p = 0.05), stiffness (p 
= 0.01) and function (p = 0.03). Both right and left quadriceps 
strength scores significantly increased (F = 3.60, p = 0.04 and F= 
5.12, p = 0.01, respectively). Furthermore, participants reduced 
their time needed to complete the TUG (F = 4.67, p = 0.02). 
Conclusions: Our results showed that subjects improved in all 
aspects of self reported pain, stiffness and function. In addition 
to perceived benefits, subjects also had significant improvements 
in quadriceps trength and locomotor performance during the six 
week course of celecoxib. 
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COMPARISON OF GLUCOSAMINE AND A PROPRIETARY 
DIETARY SUPPLEMENT FOR SYMPTOMS OF KNEE 
OSTEOARTHRITIS 
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FL 
As part of a larger study of five supplements and placebo, ex- 
ploratory comparisons of changes in symptoms of subjects with 
knee osteoarthritis between specific groups were performed. 
Eighteen subjects per group took either 1500 mg Glucosamine 
HCI (G) or a proprietary formula (1500 mg Glucosamine HCI, 250 
mg Uniflex herbal extract, 3.3 mg Sodium Hyaluronate, PF) daily 
in twelve capsules for eight weeks. PF was given in a loading 
dose of double the usual amount for the first two weeks. Uni- 
flex herbal extact consisted of a proprietary extract of Scutellaria 
baicalensis (Chinese Scullcap) and Acacia catechu (Black Cat- 
echu), with bioflavonoids baicalein and catechin as major com- 
ponents. Molecular weight of sodium hyaluronate was approxi- 
mately one million daltons. WOMAC, SF-36v2, Brief Pain Inven- 
tory and Pain Relief Diary outcomes were measured at 0, 1,2, 4, 
1 nd 8 weeks. After a one-way ANOVA (using intent-to-treat data) 
on all six groups indicated the presence of significant between- 
group differences, post-hoc comparisons of the changes from 
baseline between the G and PF groups were performed by Stu- 
dent t, Mann-Whitney U, and Fisher Exact tests. 
There were three dropouts in the G and four in the PF group. Af- 
ter one week, significant changes from baseline for efficacy mea- 
surements occurred more frequently in the PF group (16/26) than 
in the G group (3/26) (P=0.0004). PF group was significantly im- 
proved over G group at one week for SF-36v2 Physical Function 
(P=0.051) and Role Physical (P=0.049) scores. After eight weeks, 
100% of PF and 80% of G subjects reported decreased joint 
pain (by WOMAC Pain subscale and Pain Relief Diary). WOMAC 
Total scores were reduced 46% and 34% from baseline for PF 
and G groups, respectively after eight weeks (P=0.471). SF-36v2 
Physical Component Scores were improved 32% greater in the 
PF group (P=0.434). For all measurements and time points, the 
average difference between G and PF groups was 1.93x when 
PF group values were improved compared to G group values 
(P=0.014 by log-transformed t test). 
It may be tentatively concluded that the addition of an herbal ex- 
tract and hyaluronate to glucosamine led to faster and larger im- 
provements in parameters of joint health and quality of life over 
an eight week period. 
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As part of a larger study of five supplements and placebo, ex- 
ploratory comparisons of changes in symptoms of subjects with 
knee osteoarthritis between specific product groups were per- 
formed. Eighteen subjects per group took either 1500 mg Glu- 
cosamine HCI and 1200 mg Chondroitin Sulfates (GC) or a pro- 
prietary formula (1500 mg Glucosamine HCI, 250 mg Uniflex 
herbal extract, 3.3 mg Sodium Hyaluronate, PF) in twelve cap- 
sules daily for eight weeks. PF was given in a loading dose of dou- 
ble the usual amount for the first two weeks. Herbal extract con- 
sisted of a proprietary extract of Scutellaria baicalensis (Chinese 
Scullcap) and Acacia catechu (Black Catechu), with bioflavonoids 
baicalein and catechin as major components. Molecular weight 
of sodium hyaluronate was approximately one million daltons. 
WOMAC, SF-36v2, Brief Pain Inventory and Pain Relief Diary 
outcomes were measured at 0, 1,2, 4, and 8 weeks. After a one- 
way ANOVA (using intent-to-treat data) on all six groups indicated 
the presence of significant between-group differences, post-hoc 
comparisons of the changes from baseline between the GC and 
PF groups were performed by Student t, Mann-Whitney U, and 
Fisher Exact tests. 
There were four dropouts in the GC and four in the PF group. After 
one week, significant changes from baseline in efficacy measure- 
ments were found more frequently than in the PF group (16/26) 
than in the GC group (6/26) (P=0.011 by Fisher Exact test). 
After eight weeks, PF group showed larger improvements than 
GC group for WOMAC Total scores (P=0.027), Pain Relief Diary 
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scores (P=0.012), Average Pain (P=0.047), Pain Now (P=0.054), 
Pain Interference with Walking Ability (P=0.026), and Pain Inter- 
ference with Enjoyment of Life (P=0.015). SF-36v2 Physical Com- 
ponent Scores were improved 56% greater in the PF group com- 
pared to the GC group (P=0.192). After eight weeks, 100% of 
PF and 79% of GC subjects reported decreased joint pain (by 
WOMAC Pain subscale and Pain Relief Diary). For all measure- 
ments and time points, the average difference between GC and 
PF groups was 3.8x when PF group values were improved com- 
pared to GC group (P=0.014 by log-transformed t test). 
It may be tentatively concluded that a proprietary dietary sup- 
plement formula containing glucosamine, an herbal extract and 
hyaluronate led to significantly larger improvements in parame- 
ters of joint health and quality of life than the combination of glu- 
cosamine and chondroitin sulfate over an eight week period. 
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As part of a larger study of five supplements and placebo, ex- 
ploratory comparisons of changes in symptoms of subjects with 
knee osteoarthritis between specific product groups were per- 
formed. Eighteen subjects took 1500 mg glucosamine HCI and 
1200 mg chondroitin sulfates (GC) and seventeen subjects took 
1500 mg glucosamine HCI, 1200 mg chondroitin sulfates with 
3.3 mg sodium hyaluronate (GCHA) in twelve capsules daily for 
eight weeks. Molecular weight of sodium hyaluronate was approx- 
imately one million daltons. WOMAC, SF-36v2, Brief Pain Inven- 
tory and Pain Relief Diary outcomes were measured at 0, 1,2, 4, 
and 8 weeks. After a one-way ANOVA (using intent-to-treat data) 
on all six groups indicated the presence of significant between- 
group differences, post-hoc comparisons of the changes from 
baseline between the GC and MFHA groups were performed by 
Student t, Mann-Whitney U, and Fisher Exact tests. 
There were four dropouts in the GC and seven in the GCHA group 
(P=0.289). After one week, GCHA group showed greater im- 
provement in efficacy measurements compared to the GC group, 
but differences were not significant until weeks 4-8. WOMAC 
Pain scores at eight weeks for GCHA group were improved 2.3x 
compared to GC group (P=0.089), and WOMAC Total scores for 
GCHA group were improved 2.0x those of GC group (P=0.197). 
Brief Pain Inventory measurements favored GCHA group after 4 
weeks, with Pain Now, Interference with General Activity, Inter- 
ference with Mood, Interference with Walking Ability, Interference 
with Relations to Others, and Interference with Enjoyment of Life 
values showing significant improvements compared to GC group 
values. For all efficacy measurements and all time points, GCHA 
group values were significantly improved from baseline more of- 
ten than GC group values (P<0.0001 by Fisher Exact test). For 
all measurements and all time points, the average difference be- 
tween GCHA and GC groups was 4.68x when GCHA group val- 
ues were improved compared to GC group values (P=0.033 by 
Mann-Whitey U test). 
It may be tentatively concluded that addition of high-molecular 
weight hyaluronate to glucosamine and chondroitin led to signifi- 
cantly larger improvements in parameters of joint health and qual- 
ity of life than the combination of glucosamine and chondroitin 
sulfate over an eight week period. 
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TISSUE GAIN AFTER PLACEMENT OF A COLLAGEN 
MENISCUS IMPLANT FOLLOWING PARTIAL 
MENISCECTOMY 
JR Steadman 1,2, WG Rodkey 2,3, KK Briggs 2 
1Clinic, Steadman Hawkins Clinic, Vail, CO; 2Clinical and Basic 
Science, Steadman Hawkins Research Foundation, Vail, CO; 
3Scientific Affairs, ReGen Biologics, Inc., Vail, CO 
Introduction: Human menisci do not regenerate biomechanically 
competent or functional tissue after partial meniscectomy, the 
most common arthroscopic procedure performed by orthopaedic 
surgeons. Loss of meniscus tissue leads to abnormal biomechan- 
ical stresses on the chondral surfaces, often leading to degenera- 
tive osteoarthritis. The purpose of this study was to determine the 
amount of new tissue growth in patients in a randomized clinical 
trial of the Collagen Meniscus Implant (CMI) after partial medial 
meniscectomy and placement of the CMI to fill the meniscus de- 
fect compared to partial meniscectomy alone. 
Methods: Patients between 18 and 60 years of age who had un- 
dergone one to three prior partial medial meniscectomies yet had 
clinical symptoms of meniscus pathology were randomized either 
to receive the CMI or to have an additional partial meniscectomy 
(control). Twenty-one consecutive patients who met all inclusion 
criteria and had a minimum 1 -year follow-up were included. There 
were 12 CMI and 9 control patients. At index surgery, size of the 
meniscus defect was measured using specially designed instru- 
ments, and the percent of meniscus loss was calculated based 
on actual measurements. All 12 CMI patients underwent relook 
arthroscopy at one year, but control patients did not have a relook. 
At relook, the same instrumentation was used to measure the 
amount of meniscus defect filled with new tissue as a result of the 
CMI. Percent meniscus gain was calculated by multiplying the % 
meniscus loss by the % defect filled, then dividing that product by 
the difference of 100% less the % meniscus loss. 
Results: Based on direct measurements, CMI patients lost on av- 
erage 77% of their native medial meniscus, thus 23% remained. 
The control patients lost on average 75% of their medial menis- 
cus and had 25% remaining. There was no statistical difference 
between groups. It was assumed that control patients regained 
no new tissue over time based on historical controls. At 1-year 
relook, CMI patients had on average 71% of their original defect 
still filled by new tissue compared to no filling assumed in the con- 
trols. Based on the above formula, CMI patients averaged 292% 
gain in meniscus tissue compared to their original remnant. This 
difference was statistically significant (p=0.001) using an inde- 
pendent -test. 
Conclusion: The CMI supports formation of new tissue that fills 
the meniscus defect into which it is placed. The increased percent 
of meniscus gain and total amount of meniscus tissue in CMI 
patients after one year is highly statistically significant compared 
to partial meniscectomy alone. 
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PHYSICAL ACTIVITY IS ASSOCIATED WITH HIGHER 
CARTILAGE THICKNESS IN OLDER ADULTS 
DJ Hunter 1 , F Eckstein 2, MP LaValley 1 , C McLennan 1 , JB Niu 1 , 
M Hudelmaier 2, DT Felson 1 
1 Clinical Epidemiology and Research Training Unit, Boston 
University, Boston, MA; 2Institute of Anatomy & Musculoskeletal 
Research, Paracelsus Medical Private Universi~ Salzburg, 
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Physical activities are an especially important factor in either cau- 
sation of or protection against osteoarthritis. In animal studies, 
physical activity has had variable effects (from trophic to delete- 
